Bolt Biotherapeutics Reports Q1 Results, Reiterates Tight Cash Runway, Awaits Key Clinical Data
BOLT sits 22% above its 52-week low of $3.91.
Summary
Bolt Biotherapeutics reported a Q1 net loss of $7.2 million and a cash balance of $23.9 million, projecting a runway into 2027 amidst a going concern warning. The company is focused on upcoming BDC-4182 clinical data in Q3 2026, with other programs on hold.
Key Events · Earnings and Guidance · BOLT
-
Q1 2026 Financial Results
Reported a net loss of $7.2 million for the first quarter, an improvement from $11.0 million in Q1 2025, driven by reduced R&D and G&A expenses due to restructuring.
-
Tight Cash Runway
Cash, cash equivalents, and marketable securities totaled $23.9 million as of March 31, 2026, anticipated to fund operations only into 2027. This aligns with the concurrent 10-Q reiterating a going concern warning.
-
Key Clinical Data Expected
Initial clinical data from the BDC-4182 Phase 1/2 study for gastric and gastroesophageal cancer is expected in the third quarter of 2026, representing a critical milestone for the company.
-
Pipeline Programs on Hold
Two additional ISAC programs targeting CEA and PD-L1 are currently on hold, with development planned to resume only after BDC-4182 demonstrates proof-of-concept.
Analysis · BOLT · Life Sciences
Bolt Biotherapeutics announced its first quarter 2026 financial results, reporting a net loss of $7.2 million and a cash balance of $23.9 million. While the company reduced its operating loss and expenses through restructuring, its cash runway is projected only into 2027, which aligns with the concurrent 10-Q reiterating a going concern warning. The company's future hinges on the initial clinical data from its lead BDC-4182 Phase 1/2 study, expected in Q3 2026, as other pipeline programs remain on hold.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BOLT was trading at $4.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $3.91 to $9.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.